AMGN vs. JNJ: Amgen vs. Johnson & Johnson Stock Comparison

November 11, 2026

How do Amgen (AMGN) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Company profile comparison for Amgen (AMGN) and Johnson & Johnson (JNJ)
Profile Item	AMGN	JNJ
Name	Amgen Inc. Common Stock	Johnson & Johnson
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	249.05 billion USD	664.95 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 17, 1983	January 2, 1962
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AMGN

JNJ

GSPC

Amgen (AMGN) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Amgen (AMGN) and Johnson & Johnson (JNJ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Amgen (AMGN) and Johnson & Johnson (JNJ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
Total Return (1Y)	48.82%	53.82%
Total Return (3Y, Annualized)	24.31%	27.51%
Total Return (5Y, Annualized)	20.67%	14.71%

Risk Profile

Drawdown History

AMGN

JNJ

GSPC

Amgen (AMGN) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Amgen (AMGN) and Johnson & Johnson (JNJ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
Volatility (1Y, Annualized)	29.12%	21.23%
Beta (5Y)	0.43	0.21
Max Drawdown (5Y)	-24.86%	-18.41%
Avg. Volume (3M)	2.76M	6.93M

Risk-Adjusted Performance

Risk-Return Positioning

AMGN and JNJ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
Sharpe Ratio (1Y)	1.53	2.33
Sortino Ratio (1Y)	2.36	3.66

Profitability

ROE (TTM)

Both Amgen (AMGN) at 78.35% and Johnson & Johnson (JNJ) at 20.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max: 109.18%
AMGN: 78.35%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 109.18%
JNJ: 20.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Amgen (AMGN) at 24.14% keeps the most of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN: 24.14%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max: 18.05%
JNJ: 16.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max: 83.12%
AMGN: 35.79%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max: 83.12%
JNJ: 25.74%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
ROE (TTM)	78.35%	20.02%
ROA (TTM)	8.91%	8.46%
Net Margin (TTM)	24.14%	16.20%
Operating Margin (TTM)	35.79%	25.74%
Gross Margin (TTM)	72.47%	67.78%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Amgen (AMGN) at 88.23% and Johnson & Johnson (JNJ) at 90.50% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
Revenue Growth (YoY)	9.95%	6.05%
Revenue Growth (3Y CAGR)	11.77%	5.60%
EPS Growth (YoY)	88.23%	90.50%
EPS Growth (3Y CAGR)	5.52%	17.90%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.48 and Johnson & Johnson (JNJ) at 1.02 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AMGN: 1.48
Min: 0.10

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JNJ: 1.02
Min: 0.10

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Johnson & Johnson (JNJ) at 0.55 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN: 3.76
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max: 1.42
Q3: 0.65
JNJ: 0.55
Median: 0.15
Q1: 0.02
Min: 0.00

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
Current Ratio (MRQ)	1.48	1.02
Debt / Equity (MRQ)	3.76	0.55
Net Debt / EBITDA	2.31	0.79

Dividends

Dividend Yield (TTM)

Both Amgen (AMGN) at 2.16% and Johnson & Johnson (JNJ) at 1.94% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN: 2.16%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ: 1.94%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Amgen (AMGN) at 57.62% and Johnson & Johnson (JNJ) at 80.12% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN: 57.62%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ: 80.12%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
Dividend Yield (TTM)	2.16%	1.94%
Dividend Payout Ratio (TTM)	57.62%	80.12%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and Johnson & Johnson (JNJ) at 41.92 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max: 85.34
Q3: 43.46
AMGN: 26.69
Median: 26.69
Q1: 13.30
Min: 0.07

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max: 85.34
Q3: 43.46
JNJ: 41.92
Median: 26.69
Q1: 13.30
Min: 0.07

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max: 58.18
Q3: 25.77
Median: 7.30
AMGN: 6.40
Q1: 3.01
Min: 0.01

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 58.18
Q3: 25.77
Median: 7.30
JNJ: 6.69
Q1: 3.01
Min: 0.01

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Johnson & Johnson (JNJ) at 8.16 sits in the upper P/B ratio quartile, and Amgen (AMGN) at 17.35 prices even higher, above its industry range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN: 17.35
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 13.53
JNJ: 8.16
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Amgen (AMGN) vs. Johnson & Johnson (JNJ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Johnson & Johnson (JNJ)
Metric	AMGN	JNJ
P/E Ratio (TTM)	26.69	41.92
P/S Ratio (TTM)	6.40	6.69
P/B Ratio (MRQ)	17.35	8.16
Free Cash Flow Yield (TTM)	2.96%	2.78%